Xvivo Perfusion Q4: Strong end to 2018
Research Note
2019-02-08
09:00
Sales in Q4 came in higher than expected and sales related to warm perfusion showed continued strong growth. The gross margin for non-durable goods was in line with our forecast and although operating expenses were slightly higher than our expectations, the higher-than-expected sales growth resulted in an EBITDA in line with our forecast. Overall, we keep a positive view on the report, focusing on the strong result for sales related to warm perfusion. Our fair value (base case) remains unchanged.
AN
Arvid Necander
Disclosures and disclaimers